8/5/2013

The FDA should approve Bayer's experimental pulmonary hypertension drug riociguat but at lower doses than what the company sought, the agency's medical reviewers said. The drug, which will be marketed as Adempas once approved, is designed to enhance the exercise ability of patients with chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension.

Full Story:
Reuters

Related Summaries